These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 16457651)

  • 21. Poxvirus as a vector to transduce human dendritic cells for immunotherapy: abortive infection but reduced APC function.
    Jenne L; Hauser C; Arrighi JF; Saurat JH; Hügin AW
    Gene Ther; 2000 Sep; 7(18):1575-83. PubMed ID: 11021596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector.
    Terando A; Roessler B; Mulé JJ
    Cancer Gene Ther; 2004 Mar; 11(3):165-73. PubMed ID: 14726959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical trials with tumor antigen genetically modified dendritic cells.
    Ribas A
    Semin Oncol; 2005 Dec; 32(6):556-62. PubMed ID: 16338421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
    Xia D; Moyana T; Xiang J
    Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Engineering dendritic cells to enhance cancer immunotherapy.
    Boudreau JE; Bonehill A; Thielemans K; Wan Y
    Mol Ther; 2011 May; 19(5):841-53. PubMed ID: 21468005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review: dendritic cell immunotherapy for melanoma.
    Hadzantonis M; O'Neill H
    Cancer Biother Radiopharm; 1999 Feb; 14(1):11-22. PubMed ID: 10850282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Immunotherapeutic effects of beta-elemene combined with interleukin-23 gene-modified dendritic cells on murine pancreatic carcinoma].
    Tan G; Wang ZY; Wang XG; Cheng L; Yin S
    Ai Zheng; 2006 Sep; 25(9):1082-6. PubMed ID: 16965646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modifying adenoviral vectors for use as gene-based cancer vaccines.
    Basak SK; Kiertscher SM; Harui A; Roth MD
    Viral Immunol; 2004; 17(2):182-96. PubMed ID: 15279698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols.
    Dullaers M; Breckpot K; Van Meirvenne S; Bonehill A; Tuyaerts S; Michiels A; Straetman L; Heirman C; De Greef C; Van Der Bruggen P; Thielemans K
    Mol Ther; 2004 Oct; 10(4):768-79. PubMed ID: 15451461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth.
    Bryson PD; Han X; Truong N; Wang P
    Vaccine; 2017 Oct; 35(43):5842-5849. PubMed ID: 28916248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dendritic cells for specific cancer immunotherapy.
    Meidenbauer N; Andreesen R; Mackensen A
    Biol Chem; 2001 Apr; 382(4):507-20. PubMed ID: 11405216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor activity of lentivirus-mediated interleukin -12 gene modified dendritic cells in human lung cancer in vitro.
    Ahmed Ali HA; Di J; Mei W; Zhang YC; Li Y; Du ZW; Zhang GZ
    Asian Pac J Cancer Prev; 2014; 15(2):611-6. PubMed ID: 24568466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands.
    Aldrich WA; Ren C; White AF; Zhou SZ; Kumar S; Jenkins CB; Shaw DR; Strong TV; Triozzi PL; Ponnazhagan S
    Gene Ther; 2006 Jan; 13(1):29-39. PubMed ID: 16136165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of Influenza Matrix Protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells.
    Tuyaerts S; Michiels A; Corthals J; Bonehill A; Heirman C; de Greef C; Noppe SM; Thielemans K
    Cancer Gene Ther; 2003 Sep; 10(9):696-706. PubMed ID: 12944989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improvement of dendritic-based vaccine efficacy against hepatitis B virus-related hepatocellular carcinoma by two tumor-associated antigen gene-infected dendritic cells.
    Yang JY; Cao DY; Xue Y; Yu ZC; Liu WC
    Hum Immunol; 2010 Mar; 71(3):255-62. PubMed ID: 20036295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
    Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
    Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Viral vectors for dendritic cell-based immunotherapy.
    Jenne L; Schuler G; Steinkasserer A
    Trends Immunol; 2001 Feb; 22(2):102-7. PubMed ID: 11286712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Immune response of HBsAg gene-modified dendritic cell-based vaccine in HepG2. 2. 15 hepatocellular carcinoma cells].
    Yang JY; Liu WC; Cao DY; Si XM; Teng ZH
    Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):728-32. PubMed ID: 18396682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.